Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;10(1):7-13.
doi: 10.1016/j.prnil.2022.01.001. Epub 2022 Jan 11.

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

Sotaro Chikamatsu  1 , Masaki Shiota  1 , Shigetomo Yamada  1 , Leandro Blas  1 , Takashi Matsumoto  1 , Eiji Kashiwagi  1 , Junichi Inokuchi  1 , Ken-Ichiro Shiga  2 , Akira Yokomizo  2 , Masatoshi Eto  1
Affiliations

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

Sotaro Chikamatsu et al. Prostate Int. 2022 Mar.

Abstract

Background: The CHAARTED and LATITUDE trials demonstrated a survival benefit of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we examined the impact of the risk stratification criteria used in the CHAARTED and LATITUDE trials on the prognosis of castration-resistant prostate cancer (CRPC). We also tested whether these risk stratification criteria could help in selecting effective initial treatment for CRPC.

Method: Japanese patients with CRPC who were treated with docetaxel or androgen receptor pathway inhibitors such as abiraterone acetate or enzalutamide between 2014 and 2018 were included in this study. Clinicopathological factors, progression-free survival, and overall survival were investigated.

Results: Of 215 patients, 110 men (51.2%) and 93 men (43.3%) were grouped as high volume by CHAARTED criteria and high risk by LATITUDE criteria, respectively. Median progression-free survival was 10.3/4.5 months (P < 0.0001) for low/high volume (CHAARTED criteria) and 9.9/4.8 months (P = 0.0032) for low/high risk (LATITUDE criteria). The median overall survival was 44.8/17.4 months (P < 0.0001) for low/high volume (CHAARTED criteria) and 37.4/17.4 months (P = 0.0011) for low/high risk (LATITUDE criteria). The prognostic impact of CHAARTED and LATITUDE criteria was comparable between androgen receptor pathway inhibitors and docetaxel as first-line treatment for CRPC.

Conclusion: The CHAARTED and LATITUDE criteria were prognostic, but not useful to discriminate the therapeutic outcome between androgen receptor pathway inhibitors and docetaxel for CRPC.

Keywords: Androgen receptor pathway inhibitor; Androgen-deprivation therapy; Castration-resistant prostate cancer; Docetaxel; Risk stratification.

PubMed Disclaimer

Conflict of interest statement

Masaki Shiota, Akira Yokomizo, and Masatoshi Eto have received honoraria from Janssen Pharma, Astellas Pharma, AstraZeneca, Takeda Pharmaceutical, and Sanofi.

Figures

Fig. 1
Fig. 1
Progression-free survival (PFS) and overall survival (OS) in patients stratified by CHAARTED/LATITUDE criteria. (A) and (B) Kaplan–Meier survival curves of PFS (A) and OS (B) when stratified by CHAARTED criteria. (C) and (D) Kaplan–Meier survival curves of PFS (C) and OS (D) when stratified by LATITUDE criteria.
Fig. 2
Fig. 2
Progression-free survival (PFS) and overall survival (OS) in patients stratified by CHAARTED/LATITUDE criteria and androgen receptor pathway inhibitor (ARPI) or docetaxel as first-line treatment for CRPC. (A) and (B) Kaplan–Meier survival curves of PFS (A) and OS (B) when stratified by CHAARTED criteria and first-line treatment for castration-resistant prostate cancer. (C) and (D) Kaplan–Meier survival curves of PFS (C) and OS (D) when stratified by LATITUDE criteria and first-line treatment for castration-resistant prostate cancer.
Fig. 3
Fig. 3
Subgroup analysis on progression-free survival (PFS) and overall survival (OS). (A) and (B) Hazard ratio with 95% confidence interval for PFS (A) and OS (B) in each subgroup when treated with androgen receptor pathway inhibitor (ARPI) or docetaxel. P-values for hazard ratio and interaction test are provided.
See this image and copyright information in PMC

References

    1. Shiota M., Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23(5):360–369. - PubMed
    1. Choi S.Y., Ryu J., You D., Hong J.H., Ahn H., Kim C.S. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification. Int J Urol. 2019;26(1):62–68. - PubMed
    1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. - PubMed
    1. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. - PMC - PubMed
    1. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148. - PMC - PubMed